Groundbreaking Research on Multimodal AI Combined with Synthetic Data for Predicting Neuropathology of Dementia

This study proposes an innovative solution for predicting the neuropathological features of dementia during a patient's lifetime using multimodal artificial intelligence (integrating clinical data, biomarkers, and demographic information) and synthetic data augmentation technology (DDPM diffusion model), combined with the TabPFN deep learning model. It significantly improves the accuracy of early detection and provides technical support for early intervention in dementia.

Dementia is a major global health challenge amid aging, with approximately 55 million patients worldwide and nearly 10 million new cases each year, of which Alzheimer's disease accounts for 60-70%. Traditional diagnosis relies on late-stage symptoms and imaging, by which time neuronal damage is irreversible. Predicting dementia during a patient's lifetime faces challenges such as data scarcity (requiring post-mortem pathological confirmation), complex pathology, and data quality issues.

The study uses data from NACC and ROSMAP cohorts, integrating clinical assessments (MMSE scores), biomarkers (APOE genotype, CSF levels), demographics, and pathological scores (gold standard). The DDPM diffusion model is used to generate synthetic data, alleviating sample imbalance and enhancing model generalization ability.

The TabPFN deep learning model (designed specifically for tabular data, with pre-trained prior knowledge and excellent performance on small samples) is used, combined with the SHAP interpretability analysis module, to help understand feature contributions and improve clinical trust.

Through cross-dataset validation (training on NACC, testing on ROSMAP), using ROC/AUC, PR curves, and calibration curves for evaluation, the results show that the multimodal system combined with synthetic data is significantly superior to traditional methods and performs excellently in predicting pathological features such as amyloid deposition.

Methodological innovations: Expanding the application of DDPM in medical tabular data, verifying the advantages of TabPFN, and establishing a complete multimodal process. Clinical significance: Enabling early screening, personalized risk assessment, resource optimization, and accelerating the development of medical AI.

Limitations: Based on North American populations, needs to verify applicability to other ethnic groups; there is a time gap between pathological confirmation and prediction; synthetic data quality needs improvement. Future directions: Integrate longitudinal data, optimize generation models, and promote clinical translation.